The goal of this clinical research study is to learn if a decrease in the levels of prostate
specific antigen (PSA) may be linked with the status of prostate cancer that has spread to
the bones. Researchers also want to learn how changes in your blood PSA level might affect
the rebuilding of healthy bones while you are being treated with TKI258 for prostate cancer.